Somatostatinoma syndrome. Biochemical, morphologic and clinical features. 1979

G J Krejs, and L Orci, and J M Conlon, and M Ravazzola, and G R Davis, and P Raskin, and S M Collins, and D M McCarthy, and D Baetens, and A Rubenstein, and T A Aldor, and R H Unger

Diabetes mellitus, steatorrhea, cholelithiasis and a tumor distorting the duodenum prompted a work-up for somatostatinoma in a 52-year-old man. The responses of pancreatic B-cells but not of A-cells to nutrient stimuli were inhibited, and growth-hormone release was suppressed, suggesting somatostatin resistance in some target tissues. Plasma somatostatin-like immunoreactivity ranged from 9000 to 13,000 pg per milliliter (normal: 88+/-8, mean +/- S.E.M.) and was distributed in four molecular forms, including free somatostatin. The primary tumor contained 5 microgram of somatostatin-like immunoreactivity per milligram of wet tissue, distributed in three of the molecular forms noted in plasma. Plasma calcitonin was also elevated (4650 pg per milliliter; normal: less than 120). Immunocytochemical studies showed that cells of the primary tumor contained somatostatin and calcitonin but no other peptide hormones. Only somatostatin was present in the metastases. Somatostatin was localized electron microscopically in all secretory granules, irrespective of size and shape, whereas calcitonin was present only within a single subpopulation of small granules in the same cells.

UI MeSH Term Description Entries
D007031 Hypothalamus Ventral part of the DIENCEPHALON extending from the region of the OPTIC CHIASM to the caudal border of the MAMMILLARY BODIES and forming the inferior and lateral walls of the THIRD VENTRICLE. Lamina Terminalis,Preoptico-Hypothalamic Area,Area, Preoptico-Hypothalamic,Areas, Preoptico-Hypothalamic,Preoptico Hypothalamic Area,Preoptico-Hypothalamic Areas
D007515 Islets of Langerhans Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN. Islands of Langerhans,Islet Cells,Nesidioblasts,Pancreas, Endocrine,Pancreatic Islets,Cell, Islet,Cells, Islet,Endocrine Pancreas,Islet Cell,Islet, Pancreatic,Islets, Pancreatic,Langerhans Islands,Langerhans Islets,Nesidioblast,Pancreatic Islet
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D010902 Pituitary Gland A small, unpaired gland situated in the SELLA TURCICA. It is connected to the HYPOTHALAMUS by a short stalk which is called the INFUNDIBULUM. Hypophysis,Hypothalamus, Infundibular,Infundibular Stalk,Infundibular Stem,Infundibulum (Hypophysis),Infundibulum, Hypophyseal,Pituitary Stalk,Hypophyseal Infundibulum,Hypophyseal Stalk,Hypophysis Cerebri,Infundibulum,Cerebri, Hypophysis,Cerebrus, Hypophysis,Gland, Pituitary,Glands, Pituitary,Hypophyseal Stalks,Hypophyses,Hypophysis Cerebrus,Infundibular Hypothalamus,Infundibular Stalks,Infundibulums,Pituitary Glands,Pituitary Stalks,Stalk, Hypophyseal,Stalk, Infundibular,Stalks, Hypophyseal,Stalks, Infundibular
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D002096 C-Peptide The middle segment of proinsulin that is between the N-terminal B-chain and the C-terminal A-chain. It is a pancreatic peptide of about 31 residues, depending on the species. Upon proteolytic cleavage of proinsulin, equimolar INSULIN and C-peptide are released. C-peptide immunoassay has been used to assess pancreatic beta cell function in diabetic patients with circulating insulin antibodies or exogenous insulin. Half-life of C-peptide is 30 min, almost 8 times that of insulin. Proinsulin C-Peptide,C-Peptide, Proinsulin,Connecting Peptide,C Peptide,C Peptide, Proinsulin,Proinsulin C Peptide

Related Publications

G J Krejs, and L Orci, and J M Conlon, and M Ravazzola, and G R Davis, and P Raskin, and S M Collins, and D M McCarthy, and D Baetens, and A Rubenstein, and T A Aldor, and R H Unger
July 1983, Klinische Wochenschrift,
G J Krejs, and L Orci, and J M Conlon, and M Ravazzola, and G R Davis, and P Raskin, and S M Collins, and D M McCarthy, and D Baetens, and A Rubenstein, and T A Aldor, and R H Unger
January 1975, Neurology,
G J Krejs, and L Orci, and J M Conlon, and M Ravazzola, and G R Davis, and P Raskin, and S M Collins, and D M McCarthy, and D Baetens, and A Rubenstein, and T A Aldor, and R H Unger
March 1977, Lancet (London, England),
G J Krejs, and L Orci, and J M Conlon, and M Ravazzola, and G R Davis, and P Raskin, and S M Collins, and D M McCarthy, and D Baetens, and A Rubenstein, and T A Aldor, and R H Unger
May 1981, The Journal of clinical endocrinology and metabolism,
G J Krejs, and L Orci, and J M Conlon, and M Ravazzola, and G R Davis, and P Raskin, and S M Collins, and D M McCarthy, and D Baetens, and A Rubenstein, and T A Aldor, and R H Unger
November 1979, AJR. American journal of roentgenology,
G J Krejs, and L Orci, and J M Conlon, and M Ravazzola, and G R Davis, and P Raskin, and S M Collins, and D M McCarthy, and D Baetens, and A Rubenstein, and T A Aldor, and R H Unger
July 1972, Helvetica paediatrica acta,
G J Krejs, and L Orci, and J M Conlon, and M Ravazzola, and G R Davis, and P Raskin, and S M Collins, and D M McCarthy, and D Baetens, and A Rubenstein, and T A Aldor, and R H Unger
January 1991, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.),
G J Krejs, and L Orci, and J M Conlon, and M Ravazzola, and G R Davis, and P Raskin, and S M Collins, and D M McCarthy, and D Baetens, and A Rubenstein, and T A Aldor, and R H Unger
December 1959, A.M.A. journal of diseases of children,
G J Krejs, and L Orci, and J M Conlon, and M Ravazzola, and G R Davis, and P Raskin, and S M Collins, and D M McCarthy, and D Baetens, and A Rubenstein, and T A Aldor, and R H Unger
October 1993, International journal of dermatology,
G J Krejs, and L Orci, and J M Conlon, and M Ravazzola, and G R Davis, and P Raskin, and S M Collins, and D M McCarthy, and D Baetens, and A Rubenstein, and T A Aldor, and R H Unger
March 1982, Medicina clinica,
Copied contents to your clipboard!